公开(公告)号：US12128012B2

公开(公告)日：2024-10-29

申请号：US17770543

申请日：2021-05-14

Applicant: University of Kansas

Inventor： Richard Barohn ,  John A. Stanford ,  Matthew Macaluso

IPC: A61K31/135 ,  A61P25/28

CPC classification number: A61K31/135 ,  A61P25/28

Abstract: A method of treating amyotrophic lateral sclerosis (ALS) is provided to extend life expectancy in a subject. The method can include administering the ketamine to a subject having ALS such that the subject has an extended life expectancy compared to life expectancy of the subject prior to being administered the ketamine. The extended life expectancy is determined by the subject having a first progression rate of ALS prior to being administered ketamine and a second progression rate of ALS after being administered ketamine. The first progression rate is faster than the second progression rate such that the progression of ALS in the subject is slowed by the ketamine.

公开(公告)号：US11286462B2

公开(公告)日：2022-03-29

申请号：US16647345

申请日：2018-09-14

Applicant: University of Kansas

Inventor： Hiroshi Nishimune ,  Richard Barohn ,  Buddhadeb Dawn ,  Yomna Badawi ,  James W. Mitchell ,  Rupal Soder

IPC: C12N5/0775 ,  A61K35/51

Abstract: Embodiments of the present disclosure relate generally to the production of therapeutic mesenchymal stem cells (MSCs). More particularly, the present disclosure relates to the use of cell culture compositions and methods for generating MSCs that secrete neurotrophic factors and synaptic organizing agents for the treatment of neurodegenerative diseases such as Amyotrophic Lateral Sclerosis (ALS). As such, the present disclosure addresses the need for establishing a reliable source of therapeutic stem cells useful for the treatment of neurodegenerative diseases.

公开(公告)号：US20220396772A1

公开(公告)日：2022-12-15

申请号：US17582704

申请日：2022-01-24

Applicant: University of Kansas

Inventor： Hiroshi Nishimune ,  Richard Barohn ,  Buddhadeb Dawn ,  Yomna Badawi ,  James W. Mitchell ,  Rupal Soder

IPC: C12N5/0775 ,  A61K35/51

Abstract: Embodiments of the present disclosure relate generally to the production of therapeutic mesenchymal stem cells (MSCs). More particularly, the present disclosure relates to the use of cell culture compositions and methods for generating MSCs that secrete neurotrophic factors and synaptic organizing agents for the treatment of neurodegenerative diseases such as Amyotrophic Lateral Sclerosis (ALS). As such, the present disclosure addresses the need for establishing a reliable source of therapeutic stem cells useful for the treatment of neurodegenerative diseases.